Overall survival and event-free survival from date of ASCT. (A) OS from date of ASCT. With a median follow-up of 53 months, the 4-year OS post-ASCT was 65% for the TRIL cohort (blue line) and 63% for the DLBCL cohort (red line) (P = .61). (B) EFS from date of ASCT. With a median follow-up of 53 months, the 4-year EFS was 45% for the TRIL cohort (blue line) and 46% for the DLBCL cohort (red line) (P = .97).